Clinical trial
Phase II Iressa Versus Vinorelbine (INVITE)
NCT00256711 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00256711 |
|---|---|
| Title | Phase II Iressa Versus Vinorelbine (INVITE) |
| Official title | A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Gefitinib, Vinorelbine |
| Enrollment | 192 |
| Start date | Jul 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Australia, Brazil, Czechia, France, Germany, Italy, South Africa, South Korea, Taiwan, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: